BioLife Solutions Inc.宣布与Qkine Limited达成一项多年期供应合作协议，此举将推动其产品组合扩展至快速扩张的细胞因子领域。该战略合作标志着公司正式切入生物制药上游原料赛道，通过整合Qkine在重组蛋白技术方面的专长，有望为细胞与基因治疗企业提供更完整的供应链解决方案。随着全球细胞治疗商业化进程加速，高品质细胞因子需求正呈现指数级增长态势。此次布局不仅强化了BioLife在生物样本存储解决方案之外的业务矩阵，更将借助Qkine的无动物源成分生产技术，满足市场对标准化细胞培养添加剂的迫切需求。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.